Yale Jen
Stock Analyst at Laidlaw
(0.20)
# 4,710
Out of 5,124 analysts
77
Total ratings
25.3%
Success rate
-11.1%
Average return
Main Sectors:
Stocks Rated by Yale Jen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EYPT EyePoint | Downgraded: Hold | n/a | $0.3619 | - | 5 | Oct 20, 2026 | |
| AEON AEON Biopharma | Initiated Coverage: Buy | $1.8 | $0.1818 | +890.10% | 1 | Sep 9, 2026 | |
| NCEL NewcelX | Initiated Coverage: Buy | $23 | $2.78 | +727.34% | 2 | Jul 13, 2026 | |
| KZIA Kazia Therapeutics | Initiated Coverage: Buy | $25 | $7.41 | +237.38% | 1 | Apr 15, 2026 | |
| FEMY Femasys | Initiated Coverage: Buy | $130 | $1.42 | +9,054.93% | 1 | Nov 20, 2025 | |
| NSRX Nasus Pharma | Initiated Coverage: Buy | $22 | $2.94 | n/a | 1 | Sep 29, 2025 | |
| VKTX Viking Therapeutics | Reiterated: Buy | $110 | $28.99 | n/a | 3 | Aug 20, 2025 | |
| SNTI Senti Biosciences Holdings | Initiated Coverage: Buy | $5 | $0.1588 | n/a | 1 | Jun 6, 2025 | |
| ALDX Aldeyra Therapeutics | Reiterated: Buy | $11 | $0.636 | n/a | 4 | Apr 4, 2025 | |
| NVCT Nuvectis Pharma | Initiated Coverage: Buy | $19 | $21.02 | n/a | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $5.94 | n/a | 1 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 → $100 | $2.29 | n/a | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $68 | $31.00 | n/a | 8 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 → $20 | $0.6976 | n/a | 5 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $48 | $87.00 | n/a | 1 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.9495 | n/a | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $79 | $9.49 | n/a | 6 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7.5 → $225 | $0.9401 | n/a | 3 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 → $25 | $0.0001 | n/a | 5 | Jun 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $4.45 | n/a | 2 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.00645 | n/a | 2 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $1.63 | n/a | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.67 | n/a | 3 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 → $10 | $0.015 | n/a | 2 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 → $20 | $7.58 | n/a | 3 | Mar 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5.71 | $12.79 | n/a | 1 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.24 | n/a | 1 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $8.5 | $1.71 | n/a | 2 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.0002 | n/a | 2 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $0.3953 | n/a | 1 | May 20, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 → $90 | $0.5698 | n/a | 2 | Nov 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $5.05 | n/a | 1 | Sep 27, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $3.5 | $4.20 | n/a | 1 | Sep 16, 2014 |
EyePoint
Oct 20, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.3619
Upside: -
AEON Biopharma
Sep 9, 2026
Initiated Coverage: Buy
Price Target: $1.8
Current: $0.1818
Upside: +890.10%
NewcelX
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $23
Current: $2.78
Upside: +727.34%
Kazia Therapeutics
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $25
Current: $7.41
Upside: +237.38%
Femasys
Nov 20, 2025
Initiated Coverage: Buy
Price Target: $130
Current: $1.42
Upside: +9,054.93%
Nasus Pharma
Sep 29, 2025
Initiated Coverage: Buy
Price Target: $22
Current: $2.94
Upside: n/a
Viking Therapeutics
Aug 20, 2025
Reiterated: Buy
Price Target: $110
Current: $28.99
Upside: n/a
Senti Biosciences Holdings
Jun 6, 2025
Initiated Coverage: Buy
Price Target: $5
Current: $0.1588
Upside: n/a
Aldeyra Therapeutics
Apr 4, 2025
Reiterated: Buy
Price Target: $11
Current: $0.636
Upside: n/a
Nuvectis Pharma
Mar 17, 2025
Initiated Coverage: Buy
Price Target: $19
Current: $21.02
Upside: n/a
Feb 10, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $5.94
Upside: n/a
Nov 12, 2024
Reiterated: Buy
Price Target: $16 → $100
Current: $2.29
Upside: n/a
Oct 8, 2024
Reiterated: Buy
Price Target: $68
Current: $31.00
Upside: n/a
Sep 27, 2024
Reiterated: Buy
Price Target: $22 → $20
Current: $0.6976
Upside: n/a
Jul 29, 2024
Initiated Coverage: Buy
Price Target: $48
Current: $87.00
Upside: n/a
Jul 23, 2024
Downgraded: Hold
Price Target: n/a
Current: $0.9495
Upside: n/a
Jul 2, 2024
Reiterated: Buy
Price Target: $79
Current: $9.49
Upside: n/a
Jun 14, 2024
Reiterated: Buy
Price Target: $7.5 → $225
Current: $0.9401
Upside: n/a
Jun 12, 2024
Reiterated: Buy
Price Target: $11 → $25
Current: $0.0001
Upside: n/a
Dec 22, 2023
Downgraded: Hold
Price Target: n/a
Current: $4.45
Upside: n/a
Dec 12, 2023
Downgraded: Hold
Price Target: n/a
Current: $0.00645
Upside: n/a
Aug 28, 2023
Initiated Coverage: Buy
Price Target: $10
Current: $1.63
Upside: n/a
Aug 15, 2023
Downgraded: Hold
Price Target: n/a
Current: $1.67
Upside: n/a
Aug 7, 2023
Reiterated: Buy
Price Target: $30 → $10
Current: $0.015
Upside: n/a
Mar 14, 2022
Reiterated: Buy
Price Target: $18 → $20
Current: $7.58
Upside: n/a
Nov 9, 2020
Reiterated: Buy
Price Target: $5.71
Current: $12.79
Upside: n/a
Aug 24, 2020
Downgraded: Hold
Price Target: n/a
Current: $0.24
Upside: n/a
Jul 31, 2020
Reiterated: Buy
Price Target: $6 → $8.5
Current: $1.71
Upside: n/a
Aug 9, 2019
Downgraded: Hold
Price Target: n/a
Current: $0.0002
Upside: n/a
May 20, 2019
Initiated Coverage: Buy
Price Target: $10
Current: $0.3953
Upside: n/a
Nov 15, 2018
Reiterated: Buy
Price Target: $4 → $90
Current: $0.5698
Upside: n/a
Sep 27, 2016
Reiterated: Hold
Price Target: n/a
Current: $5.05
Upside: n/a
Sep 16, 2014
Initiated Coverage: Buy
Price Target: $3.5
Current: $4.20
Upside: n/a